⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

February 1, 2026Best Practice & Research Clinical Endocrinology & Metabolism

Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas

Yaron Rudman ILAN SHIMON

View at Publisher

Ask AI

Bookmark

Share

Key Points

Dopamine agonist treatment significantly improves hormonal response in patients with prolactinomas, promoting effective management of the condition.
In a cohort of patients undergoing treatment, long-term outcomes show sustained hormonal control and reduced tumor size after therapy.
Analysis across multiple settings highlights the efficacy of dopamine agonists in managing prolactinomas effectively over extended periods.
These findings may enable more tailored treatment plans and underlines the importance of monitoring long-term outcomes in prolactinoma management.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Observational analysis reveals hormonal response improvement in prolactinomas, suggesting effective treatment options.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rudman et al. (2026) studied this question.

synapsesocial.com/papers/69a76209c6e9836116a3020c https://doi.org/10.1016/j.beem.2026.102095

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Understanding septo-optic dysplasia: endocrine implications and ophthalmic consequencesBest Practice & Research Clinical Endocrinology & Metabolism · 2026
2HeteroGeNETics: Neuroendocrine tumor genetics reflect their heterogeneous complex diversityBest Practice & Research Clinical Endocrinology & Metabolism · 2026
3Effects of prolonged physical training on skeletal muscle mass accrual throughout the life spanBest Practice & Research Clinical Endocrinology & Metabolism · 2026
4Stress and the interaction of the hypothalamic–pituitary–adrenal axis with other pituitary axes and its consequences on muscle massBest Practice & Research Clinical Endocrinology & Metabolism · 2026
5Influence of the adaptation of lactate accumulation rate through physical training on muscle mass regulationBest Practice & Research Clinical Endocrinology & Metabolism · 2026
6Key hormones for the control of muscle mass: MyokinesBest Practice & Research Clinical Endocrinology & Metabolism · 2026
7Control of muscle mass during growth and aging: Clinical targets and pathwaysBest Practice & Research Clinical Endocrinology & Metabolism · 2026
8Thyroid hormones as permissive regulators of skeletal muscle protein accretion and oxidative capacity: Implications for resistance and endurance trainingBest Practice & Research Clinical Endocrinology & Metabolism · 2026
9Effects of secondary plant metabolites on expression and activation of the insulin-like growth factor system in skeletal muscleBest Practice & Research Clinical Endocrinology & Metabolism · 2026
10Genetic endocrine tumours focusing on pituitary tumoursBest Practice & Research Clinical Endocrinology & Metabolism · 2026

More from Best Practice & Research Clinical Endocrinology & Metabolism

More from Rabin Medical Center